losartan has been researched along with Tetralogy of Fallot in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Tetralogy of Fallot: A combination of congenital heart defects consisting of four key features including VENTRICULAR SEPTAL DEFECTS; PULMONARY STENOSIS; RIGHT VENTRICULAR HYPERTROPHY; and a dextro-positioned AORTA. In this condition, blood from both ventricles (oxygen-rich and oxygen-poor) is pumped into the body often causing CYANOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot." | 9.27 | Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy ( Berbee, JK; Boekholdt, SM; Bokma, JP; Bouma, BJ; Groenink, M; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2018) |
| " The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot." | 5.27 | Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy ( Berbee, JK; Boekholdt, SM; Bokma, JP; Bouma, BJ; Groenink, M; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2018) |
| "The REDEFINE is an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled trial to study the effects of the angiotensin II receptor blocker losartan (target dosage of 150 mg once daily) in adult patients with TOF." | 2.84 | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial. ( Berbee, JK; Bokma, JP; Bouma, BJ; Kornaat, EM; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woudstra, OI | 1 |
| Ghanam, A | 1 |
| Vliegen, HW | 3 |
| van Dijk, APJ | 1 |
| van Melle, JP | 3 |
| Groenink, M | 2 |
| Meijboom, FJ | 3 |
| Post, MC | 3 |
| Mulder, BJM | 3 |
| Bouma, BJ | 3 |
| Bokma, JP | 3 |
| Winter, MM | 2 |
| Kornaat, EM | 1 |
| van Dijk, AP | 2 |
| Berbee, JK | 2 |
| Zwinderman, AH | 2 |
| Boekholdt, SM | 1 |
| Reddy, S | 1 |
| Bernstein, D | 1 |
| Newburger, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System[NCT02010905] | Phase 2 | 120 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for losartan and Tetralogy of Fallot
1 other study available for losartan and Tetralogy of Fallot
| Article | Year |
|---|---|
Renin-Angiotensin-Aldosterone System Inhibitors for Right Ventricular Dysfunction in Tetralogy of Fallot: Quo Vadis?
Topics: Adult; Double-Blind Method; Humans; Losartan; Renin-Angiotensin System; Tetralogy of Fallot; Ventric | 2018 |